CervoMed (NASDAQ:CRVO) Upgraded at D. Boral Capital

D. Boral Capital upgraded shares of CervoMed (NASDAQ:CRVO) from a hold rating to a buy rating in a research note published on Wednesday morning,Benzinga reports. D. Boral Capital currently has $10.00 target price on the stock.

A number of other brokerages have also commented on CRVO. Brookline Capital Management lowered shares of CervoMed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Roth Capital upgraded shares of CervoMed to a “strong-buy” rating in a research note on Thursday, December 5th. HC Wainwright cut CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. Chardan Capital reissued a “neutral” rating on shares of CervoMed in a report on Wednesday, December 11th. Finally, Canaccord Genuity Group dropped their price objective on shares of CervoMed from $65.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.43.

CervoMed Trading Down 2.1 %

CRVO stock opened at $2.28 on Wednesday. CervoMed has a 52 week low of $1.80 and a 52 week high of $26.38. The company has a fifty day simple moving average of $2.22 and a two-hundred day simple moving average of $9.43.

Hedge Funds Weigh In On CervoMed

A number of institutional investors and hedge funds have recently made changes to their positions in CRVO. Woodline Partners LP acquired a new stake in CervoMed in the fourth quarter valued at approximately $175,000. Nuveen Asset Management LLC lifted its position in shares of CervoMed by 113.6% during the 4th quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock worth $97,000 after buying an additional 22,104 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in CervoMed in the fourth quarter valued at $32,000. Mariner LLC purchased a new position in shares of CervoMed during the fourth quarter worth about $30,000. Finally, DRW Securities LLC acquired a new stake in shares of CervoMed during the fourth quarter worth about $30,000. 25.15% of the stock is owned by institutional investors and hedge funds.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.